Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2

Ariana Ghez Farrell1,¶, Bernadeta Dadonaite1,¶, Allison J. Greaney1,2, Rachel Eguia1, Andrea N. Loes1, Nicholas M. Franko3, Jennifer Logue3, Juan Manuel Carreño4, Anass Abbad4, Helen Y. Chu3, Kenneth A. Matreyek5, Jesse D. Bloom1,6,#

Affiliations:
1Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center
2Department of Genome Sciences & Medical Scientist Training Program, University of Washington
3Division of Allergy and Infectious Diseases, University of Washington
4Department of Microbiology, Icahn School of Medicine at Mount Sinai
5Department of Pathology, School of Medicine, Case Western Reserve University
6Howard Hughes Medical Institute
¶These authors contributed equally to this work.
#Lead Contact jbloom@fredhutch.org

Abstract
Neutralization assays are experimental surrogates for the effectiveness of infection- or vaccine-elicited polyclonal antibodies and therapeutic monoclonal antibodies targeting SARS-CoV-2. However, the measured neutralization can depend on details of the experimental assay. Here we systematically assess how ACE2 expression in target cells affects neutralization by antibodies to different spike epitopes in lentivirus pseudovirus neutralization assays. For high ACE2-expressing target cells, receptor binding domain (RBD) antibodies account for nearly all neutralizing activity in polyclonal human sera. But for lower ACE2-expressing target cells, antibodies targeting regions outside the RBD make a larger (although still modest) contribution to serum neutralization. These serum-level results are mirrored for monoclonal antibodies: N-terminal domain (NTD) antibodies and RBD antibodies that do not compete for ACE2 binding incompletely neutralize on high ACE2-expressing target cells, but completely neutralize on cells with lower ACE2 expression. Our results show that ACE2 expression level in the target cells is an important experimental variable, and that high ACE2 expression emphasizes the role of a subset of RBD-directed antibodies.

Introduction
Neutralization assays are the most widely used experimental method to assess immunity elicited by SARS-CoV-2 vaccination and infection. However, the neutralization measured in the lab depends on the details of the assay. Different assays use both different viral systems (live virus versus pseudovirus) [1-4] and different target cells (cells engineered to overexpress ACE2
versus cells that endogenously express ACE2, such as Vero) [5–7]. Previous studies have shown that some antibodies can have markedly different neutralizing activities depending on which viral systems [1,3,8–10] or target cells [5–7,11] are used.

Here we systematically assess how target-cell ACE2 expression impacts the contribution of different types of antibodies to the neutralizing activity of polyclonal serum as measured in lentiviral pseudotype assays. We show that RBD-targeting antibodies contribute more to serum neutralization when target cells express more ACE2. We also show that individual monoclonal antibodies targeting epitopes outside the receptor-binding motif of the RBD have much poorer neutralization on high versus low ACE2-expressing target cells. Overall, our work demonstrates that ACE2 expression in target cells dramatically influences measured neutralization by some antibodies, and that RBD-targeting antibodies contribute comparatively more to neutralization in high ACE2-expressing target cells.

Results

293T target cells expressing different amounts of ACE2 protein
To investigate the effect of target-cell ACE2 expression on SARS-CoV-2 neutralization, we exploited a previously described method for creating HEK 293T cells with defined ACE2 protein expression levels [12]. Briefly, this method involves integrating a single copy of the ACE2 gene into an engineered locus in the 293T cell’s genome, and modulating protein expression level by altering the Kozak sequence [12]. Using this approach, we generated 293T clones expressing very-low, low, medium and high levels of ACE2 (Fig. 1A). The level of ACE2 expression across these clones spans a range of ~30 fold. The “high” 293T cell clone is most similar in ACE2 expression to previously described 293T-ACE2 cells [13] commonly used in lentiviral pseudotype neutralization assays (Fig. S1A). We also compared the ACE2 expression in the 293T clones to Vero E6 cells, which are commonly used for VSV pseudotyped assays and live-virus neutralization assays [6,14]. Vero E6 cells have a wider range of ACE2 expression than our ACE2-expressing 293T clones, but are most similar in mean expression to the “very-low” 293T clone (Fig. 1A).

As expected, the infectability of the 293T clones by spike-pseudotyped lentiviral particles paralleled their ACE2 expression (Fig. 1B), with the “very low” clone (which expressed ~30-fold less ACE2) being ~8-fold less infectable.

Target-cell ACE2 expression affects the contribution of RBD-targeting antibodies to neutralization by polyclonal serum
Prior studies using high-ACE2 expressing cells have suggested that RBD-targeting antibodies are responsible for the majority of neutralizing activity in polyclonal human sera [15–19]. To
assess if the importance of RBD-targeting antibodies for neutralization depends on target-cell ACE2 expression, we depleted RBD-targeting antibodies from polyclonal sera (Fig 2A, Fig S2) from human individuals who were infected with SARS-CoV-2 in early 2020 and then vaccinated with either Pfizer or Moderna mRNA vaccines in early 2021. We then performed spike-pseudotyped (Wuhan-Hu-1 with D614G) lentiviral neutralization assays on all four 293T cell clones with different ACE2 expression levels using RBD-depleted and non-depleted sera.

RBD-targeting antibodies were responsible for a larger share of the overall serum neutralizing activity when the target cells expressed high levels of ACE2 (Fig 2B,C,D). For instance, RBD-targeting antibodies contributed ~99% of the neutralizing activity measured using the high ACE2 cells, but only ~90% of the neutralizing activity measured using the low and very-low ACE2 cells (Fig 2B,C,D). These results show that while RBD-targeting antibodies provide the majority of neutralization measured at all target-cell ACE2 expression levels, their relative contribution is larger in high ACE2 cells (where they contribute almost all the activity) than low ACE2 cells (where non-RBD antibodies make an appreciable minority contribution to the overall neutralizing activity) (Fig 2D).

There was also a modest trend for the overall measured serum neutralization titers to be greater in cells that expressed lower levels of ACE2 (Fig 2B). This was true for both the non-depleted and RBD-depleted sera, but the trend was much stronger for the RBD-depleted sera. In particular, RBD-depleted sera always retained measurable neutralizing activity in the very-low, low and medium ACE2 target cells, but some sera lost all detectable neutralization in the high ACE2 target cells (Fig 2B).

Monoclonal antibodies to epitopes outside the RBD’s receptor-binding motif are much less potent on high ACE2 target cells

To better understand why the RBD-targeting portion of polyclonal serum makes a larger contribution to neutralization in high ACE2 target cells, we examined neutralization by monoclonal antibodies targeting distinct epitopes in spike. We selected three monoclonal antibodies: Ly-CoV555 binds to the receptor-binding motif of the RBD and competes with ACE2 binding, S309 binds the RBD outside receptor binding motif and does not compete with ACE2 binding, and 4A8 binds the N-terminal domain (NTD).

We found that antibodies that bound outside the receptor-binding motif were much less potent on target cells that expressed high levels of ACE2 (Fig 3). Specifically, the ACE2-competing antibody that binds the receptor-binding motif (Ly-CoV555) was only modestly affected by target-cell ACE2 expression level, achieving full neutralization on all target cells with a ~5-fold reduction in inhibitory concentration 50% (IC_{50}) on the high ACE2 target cells relative to the very-low ACE2 cells. In stark contrast, neutralization by the two antibodies that bound outside the receptor-binding motif was dramatically impaired on high ACE2 target cells. Neither the NTD-targeting antibody 4A8 nor ACE2-non-competing RBD
antibody S309 achieved full neutralization on the high ACE2 cells even at a very high concentration. However, both antibodies showed much better neutralization in lower ACE2 cells, with S309 achieving full neutralization and 4A8 reaching a plateau of ~90% neutralization (as opposed to ~50% plateau on high ACE2 cells) (Fig 3). Overall, these monoclonal antibody results suggest a mechanistic explanation for the serum results described above: antibodies that target epitopes outside the RBD’s receptor-binding motif are much less potent on high ACE2 target cells.

**Discussion**

Our results show that RBD-directed antibodies make a greater contribution to viral neutralization when the target cells express high levels of ACE2. This finding was consistent over ten different human sera: on high ACE2-expressing target cells, RBD-directed antibodies were consistently responsible for ~99% of the neutralizing activity of human sera, whereas on lower ACE2 levels expressing cells their activity dropped to ~80-95%. So while our results corroborate prior studies showing that RBD antibodies are the dominant contributors to serum neutralization [15–19], they also show that the magnitude of this dominance depends on the ACE2 expression level of the target cell.

Our experiments with monoclonal antibodies provide some insight into why RBD-directed antibodies contribute more to serum neutralization in cells with high ACE2 expression. Neutralization by a RBD-targeting antibody that directly competes with ACE2 for RBD binding is only modestly affected by target-cell ACE2 expression level. But both a RBD-targeting antibody that targets a non-ACE2 competing epitope and a NTD-targeting antibody neutralize much more poorly on cells with high ACE2 expression; similar results have been reported by other studies [5–7]. Therefore, in the context of polyclonal serum, the relative neutralization contributions of antibodies targeting different epitopes shifts with target cell ACE2 expression. Why the neutralization potency of different antibodies differs based on ACE2 expression remains unclear, in part because the neutralization mechanisms of non-ACE2-competing antibodies are still incompletely understood [1,20–24]. We also note that there is literature suggesting neutralization of other viruses by antibodies and drugs sometimes depends on target-cell receptor expression [25,26].

Our study is unable to definitively answer the most important question it raises: What target cell ACE2 expression provides the most biologically relevant measure of SARS-CoV-2 neutralization? Serum neutralizing antibody titers are a correlate of protection for SARS-CoV-2 [27–29], meaning neutralization titers measured in the lab correlate with protection in humans, although the exact levels of neutralizing antibodies associated with protection are not defined. However, laboratory work alone cannot determine which target cells provide experimentally measured titers most predictive of human protection—although we do note that the airway cells...
infected during typical human cases express fairly low levels of ACE2 [30,31]. The possibility that lower ACE2 expressing target cells may be more biologically relevant is also supported by the observation that the monoclonal antibody S309 (sotrovimab) provides strong protection in humans despite achieving potent neutralization only when measured in low or moderate ACE2-expression target cells [1,6,32].

A limitation of our study is that we only measured neutralization with spike-pseudotyped lentiviral particles, and did not perform multi-cycle neutralization assays with authentic SARS-CoV-2 [6,33,34] or spike-expressing chimeric VSV [2,11,14,18]. However, some prior studies using authentic SARS-CoV-2 have suggested that neutralization by non-ACE2 competing RBD antibodies is more potent on cells expressing lower ACE2 [6,7], suggesting the trends we observe likely extend beyond spike-pseudotyped lentiviral particles.

The most important implication of our work is that target cell ACE2 expression is an important experimental variable for SARS-CoV-2 neutralization assays. For instance, some new SARS-CoV-2 vaccine candidates attempt to elicit higher levels of antibodies to more conserved non-ACE2-competing RBD epitopes [35] or non-RBD regions of the spike [36]. The measured neutralization titers elicited by such vaccine candidates are likely to depend to some extent on target cell ACE2 expression. A similar dependence is likely when assessing relative neutralization of different SARS-CoV-2 variants of concern, which often have mutations both within and outside the ACE2-binding motif of the RBD. Careful reporting of ACE2 expression by the target cells used to assess neutralization titers will therefore aid in interpreting and comparing neutralization studies of different vaccine candidates and viral variants.

**Materials and Methods**

**Generation of 293T cells engineered to express different levels of ACE2**

We used previously described 293T-based landing pad cells to create cell clones that express different levels of ACE2 by modifying the Kozak sequence controlling translation of the gene [37]. Prior to modification, these HEK 293T LLP-Int-BFP-ires-iCasp9-Blast clone 3 landing pad cells [37] were maintained in D10 growth media (Dulbecco’s Modified Eagle Medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine) supplemented with 2 µg/mL doxycycline and 10 µg/mL blasticidin. These landing pad cells were modified with ACE2 transgenic sequences by transfecting 600,000 cells with 1,200 ng of Kozak-variable AattB_\text{ACE2}-miRFP670_\text{ires}_m\text{Cherry-H2A-P2A-PuroR} recombination plasmid mixed with 5 µL of Fugene 6 reagent per 6-well. The Kozak sequences preceding ACE2 were GCCACCAGT, TATCTAATG, TATTTCATG, and AATTTTATG corresponding to "high", "medium", "low", and "very low" cells, respectively [12]. The cells were transfected in D10 + doxycycline growth media until day 3 after transfection, when AP1903 (ApexBio, B4168) was added to a final concentration of 10 nM to kill off unmodified landing pad cells. Once the cells reached ~ 10% confluence, the cells were switched to D10 + doxycycline growth media containing 1 µg/µL puromycin to achieve a roughly pure population of ACE2 transgenic cells.
Cell lines

293T clones expressing different levels of ACE2 (described above) were grown in D10 growth media supplemented with 2 µg/mL doxycycline, which is required to induce their ACE2 expression from a landing pad. After several passages, 0.75 µg/mL of puromycin were added to the cell media to remove cells no longer expressing the transgenic locus.

For Fig. 1A, we used Vero E6 (American Type Culture Collection, CRL-1586) to look at endogenous ACE2 expression in these cells, and 293T cells (American Type Culture Collection, CRL-3216) for the “no ACE2” control. For Fig. S1, the 293T-ACE2 cells are those previously described in [13] (available at Biodefense and Emerging Infectious Research Resources Repository, NR-52511) and the 293T-ACE2-TMPRSS2 cells are those described in [38], and were a gift from Carol Weiss. Vero E6, 293T, 293T-ACE2 and 293T-ACE2-TMPRSS2 cells were maintained in standard D10 growth media.

Flow cytometry analysis for ACE2 expression

Cells were plated at 5 x 10⁵ cells per well in a 6-well plate. For 293T clones expressing different levels of ACE2, 2 µg/mL of doxycycline were added to cell media during plating. The next day cells were trypsinized and centrifuged at 300 x g for 4 min. After washing with 1 ml of FACS buffer (phosphate-buffered saline (PBS) + 2% bovine serum albumin (BSA)), cells were resuspended in 500 µl of rabbit anti-ACE2 antibody (Abcam, ab272500) at 1 µg/mL. After 1 h incubation on a rotator at 4°C, cells were washed with 1 ml of FACS buffer and resuspended in 500 µl of goat anti-rabbit Alexa Fluor 488 antibody (Abcam, ab150077) at 0.67 µg/ml. After 1 h incubation on a rotator at 4°C, cells were washed twice and resuspended in 500 µl of FACS buffer. Cells were analyzed by flow cytometry using the BD LSRFortessa X-50 cytometer and data was plotted using FlowJo software. Geometric mean fluorescence values were used to determine ACE2 expression relative to “high” clone.

Generation of spike-pseudotyped lentiviral particles

Lentiviral pseudotyping was performed as previously described in [13]. To generate pseudoviruses the following plasmids were used: codon optimized Wuhan-Hu-1 spike expression plasmid containing D614G mutation and 21 amino acid deletion in the C-terminal domain (sequence and plasmid available from BEI, NR-53765); lentiviral helper plasmid encoding Gag/Pol (NR-52517); pHAGE6_Luc_IRES_ZsGreen plasmid encoding luciferase and ZsGreen reporter genes in a lentiviral backbone.

To generate spike-pseudotyped lentiviral particles, 293T cells were seeded at 2.5 x 10⁶ cells per 10cm dish. 16-24 h later, cells were transfected using 15 µL of BioT transfection reagent (Bioland Scientific) with 5.7 µg of a lentiviral backbone plasmid, 2.6 µg of Gag/Pol helper plasmid, and 1.7 µg of spike expression plasmid. At 24 hours post transfection, cell culture media was replaced with fresh D10 media. At ~60 h post transfection, virus in cell media was harvested by passing cell supernatant through a surfactant-free cellulose acetate 0.45µm syringe filter (Corning, 431220), and stored at -80.

Titering of spike-pseudotyped lentiviral particles
Very low, low, medium and high ACE2 clones were seeded onto a poly-L-lysine-coated black-walled 96-well plate at 1.25 x 10⁴ cells per well in 50 µL D10 growth media, supplemented with 2 µg/ml doxycycline and 2.5 µg/ml of amphotericin B. The next day, 100 µL of serially diluted virus were added to each well. At ~48-50 hours post infection, luciferase activity was measured using the Bright-Glo Luciferase Assay System (Promega, E2620). The bottom of each plate was covered with a black bottom sticker (Thermo Fisher Scientific, NC9425162) and luciferase activity was read using a Tecan infinite M1000Pro plate reader. Dilution series were used to calculate virus titers in relative luciferase units (RLU) per µL.

**Human sera**

Serum samples were collected with informed, written consent as part of the prospective longitudinal Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) cohort of individuals with SARS-CoV-2 infection in Seattle, WA. Samples were collected between January and June 2021. The ten serum samples used in this study come from individuals who were infected with SARS-CoV-2 between March and June of 2020 and were subsequently vaccinated. The samples were from 7 females and 3 males, age range 36-72 years, mean age 50.3 years (Supplementary Table 1). Samples were collected an average of 390 days (range 296-454 days) post symptom onset and an average of 18 days (range 8-36) post second dose of a primary mRNA vaccine series. All sera was heat-inactivated at 56°C for 60 minutes prior to storage at -80°C.

**Depletion of RBD-binding antibodies from sera**

SARS-CoV-2 Wuhan-Hu-1 RBD-coupled magnetic beads (AcroBiosystems Inc, MBS-K002) were reconstituted at 1 mg/ml in assay buffer (PBS + 0.05% BSA) and washed three times with fresh assay buffer, each time maintaining 1 mg/ml concentration. Washed beads were mixed with sera at a ratio of 3 parts beads to 1 part sera, and incubated with end to end rotation for 2 h at room temperature or at 4°C overnight. After incubation, a magnet was used to separate the beads (along with RBD-binding antibodies) from the supernatant (containing the non-RBD-binding antibodies) and the supernatant was transferred to a tube of fresh beads for another round of depletion. A total of four rounds of depletion were performed for each sera, and beads were each time applied at a ratio of 3 parts beads to 1 part sera. An aliquot of sera after each round of depletion was reserved for enzyme-linked immunosorbent assay (ELISA) and kept at 4°C. Non-depleted sera was diluted to the same degree as the final dilution of depleted sera (1:4) in PBS + 0.05% BSA, dictated by the 3:1 beads-to-sera ratio.

**Measurement of sera binding to RBD by enzyme-linked immunosorbent assay (ELISA)**

ELISA experiments for sera RBD-binding were performed as previously described in [39]. Immulon 2HB plates 96-well plates (Thermo Scientific 3455) were coated with 50µl of Wuhan-Hu-1 RBD protein (gift of Institute for Protein Design) at 0.5 µg/mL in PBS and stored at 4°C overnight. The next day, plates were washed three times with PBS containing 0.1% Tween 20 (PBS-T) using a plate washer (Tecan HydroFlex) and then 200µl of blocking buffer (PBS-T containing 3% nonfat dry milk) was added to each well. Plates were incubated at room temperature for 1 h. In a separate plate, RBD-depleted and non-depleted sera were serially diluted (starting at 1:100 dilution) in PBS-T containing 1% nonfat dry milk. Blocking buffer from the RBD-covered plate was removed and 100µL of diluted sera were added to each well. After a 2 h
incubation at room temperature, plates were washed three times using a plate washer, and 50 µl of Human IgG-Fc Fragment Antibody (Bethyl Laboratories, A80-104P) at 0.33 µg/mL were added to each well. Plates were incubated at room temperature for 1 h and then washed three times using a plate washer. Following the wash, 100 µL of TMB/E horseradish peroxidase (HRP) substrate (Millipore Sigma, ES001) were added to each well. After a 5 min incubation, the reaction was stopped by adding 100 µl of 1 N HCl per well. OD$_{450}$ values were read on a Tecan infinite M1000Pro plate reader.

**Spike-pseudotyped lentivirus neutralization assays**

Very low, low, medium, and high clones were seeded at 2.5 x 10^4 cells per well onto poly-L-lysine coated black-walled 96-walled plates in 50 µl D10 media supplemented with 2 µg/mL of doxycycline and 2.5µg/mL amphotericin B. The next day, the depleted and non-depleted sera were serially diluted (starting with a 1:25 dilution) and mixed with pseudovirus at a 1:1 ratio. The virus-sera mix was incubated for 1 h at 37°C and then 100 µL was added to the pre-seeded plates. The same virus stock and dilution was always used for matched depleted and non-depleted sera across all four cell clones (targeting >500k RLUs per well). Each sample was run in duplicate, and each row contained two inoculated no-serum positive controls and one no-infection negative control. After 48-50 h incubation, luciferase activity was measured using the Bright-Glo Luciferase Assay System (Promega E2610). A black sticker was applied to the bottom of each plate to reduce background and luciferase activity was measured using the Tecan infinite M1000Pro plate reader.

Fraction infectivity was calculated for each serum-containing well by subtracting background signal from the negative control and normalizing by the average of two positive control wells in the same row. Inhibitory concentration 50% (IC$_{50}$) and its reciprocal, neutralization titer 50% (NT$_{50}$) were calculated using the neutcurve software package ([https://jbloomlab.github.io/neutcurve/](https://jbloomlab.github.io/neutcurve/), version 0.5.7), by fitting a Hill curve and fixing the top of the curve to one and bottom to zero.

For neutralization assays using monoclonal antibodies the following modifications to the above protocol were made: starting dilution for Ly-CoV555 was 0.667 µg/mL, for S309 was 6 µg/mL, and for 4A8 was 1µg/mL; IC$_{50}$ values were calculated by fixing the top of the neutralization curve to one and leaving the bottom unfixed.

**Supplemental Materials**

Figure S1: ACE2 expression in previously published ACE2 over-expressing 293T cells commonly used for spike-pseudotyped lentiviral neutralization assays. Figure S2: ELISAs showing depletion of RBD-targeting antibodies from sera. Figure S3: Full spike-pseudotyped lentiviral particle neutralization curves for RBD-depleted or non-depleted sera that are summarized in Figure 2. Table S1: Characteristics of sera used in this study.

**Funding**

This work was funded in part with federal funds from the NIH under Contracts No. 75N93021C00015 and HHSN272201400006C, and R01AI1417097 (to JDB), and R35GM142886 (to KAM). BD was funded by EMBO under grant ALTF 81-2020. JDB is an Investigator of the Howard Hughes Medical Institute.
Acknowledgements
We thank Tyler N. Starr for useful discussions and Florian Krammer for experimental resources.

Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the University of Washington (protocol #STUDY00000959 and 11/19/2020).

Informed Consent Statement
Samples were collected from individuals enrolled in a prospective longitudinal cohort study in Seattle. Written, informed consent was obtained from all participants in the study.

Data Availability Statement
Code used to analyze and plot ACE2 expression, virus titers, and virus neutralization is available at https://github.com/jbloomlab/Ace2_expression_neuts.

Conflicts of Interest
JDB consults for Apriori Bio, Oncorus, and Merck on topics related to viruses or vaccines, and recently consulted for Moderna. JDB, AJG, and ANL receive a share of IP as inventors on Fred Hutch licensed patents related to viral deep mutational scanning. HYC reported consulting with Ellume, Pfizer, The Bill and Melinda Gates Foundation, Abbvie, and Merck. She has received research funding from Gates Ventures and support and reagents from Ellume and Cepheid outside of the submitted work.
Fig. 1. 293T cell clones expressing ACE2 at different levels. (A) ACE2 expression in 293T cells engineered to express different levels of ACE2. ACE2 surface expression was measured by flow cytometry, and the histograms show the distribution of expression levels over a population of cells. Vero E6 cells are included for comparison. (B) Relationship between ACE2 expression in the four 293T target cell clones and infection by lentiviral particles pseudotyped with the SARS-CoV-2 D614G spike.
Fig. 2. RBD-targeted antibodies make a larger contribution to serum neutralization when target cells express higher levels of ACE2. (A) Process for depleting RBD-targeted antibodies
from polyclonal human serum. RBD-coupled magnetic beads are incubated with sera. The RBD-targeting antibodies bind the beads, and are then removed from sera by magnetic separation. RBD-targeting antibody depletion was confirmed by ELISA (Fig S2). This figure was created with BioRender.com. (B) Neutralization of D614G spike-pseudotyped lentiviral particles by polyclonal human sera from ten different individuals with or without depletion of RBD-targeting antibodies, as measured on target cells expressing different levels of ACE2. Neutralization is reported as the neutralization titer 50% (NT$_{50}$), which is the reciprocal serum dilution that neutralizes half the virus. The dashed red line represents the limit of detection (NT$_{50}$ of 25), and values less than this limit are assigned a value of 25. (C) Fold decrease in neutralization after depleting the RBD antibodies and (D) percent of neutralization due to RBD-targeting antibodies for the sera shown in panel B. Calculated by subtracting NT$_{50}$ values for depleted sera from non-depleted sera and expressed as percentage of non-depleted sera neutralization.
Fig. 3. High ACE2 expression in target cells strongly reduces neutralization by monoclonal antibodies that bind spike epitopes outside the receptor-binding motif. Neutralization curves for three monoclonal antibodies that target different epitopes: Ly-CoV555 binds the RBD’s receptor-binding motif and competes with ACE2 binding, S309 binds a RBD epitope outside the receptor-binding motif, and 4A8 binds the NTD. The dashed gray line indicates zero infectivity. Neutralization assays were performed using D614G spike-pseudotyped lentiviral particles.
Fig. S1. ACE2 expression in previously published ACE2 over-expressing 293T cells commonly used for spike-pseudotyped lentiviral neutralization assays. This figure compares ACE2 expression in the high and medium ACE2 cells described in the current paper (Fig 1A) to the 293T-ACE2 cells described by [13]) and 293T-TMPRSS2-ACE2 cells described by [38]). These data were acquired in a separate experiment from that shown in Fig. 1A. The medium and high ACE2 cell clones were not pre-treated with puromycin to purge cells that had lost ACE2 expression prior to running this experiment, likely explaining the larger tail of non-expressing cells relative to Fig. 1A.
**Fig. S2. ELISAs showing depletion of RBD-targeting antibodies from sera.** ELISA binding curves for sera samples used in lentiviral pseudotype neutralization assays shown in Fig 2. Sera were depleted of RBD-targeting antibodies using four rounds of the process shown in Fig 2A, and binding to RBD was measured by ELISA after each round.
ACE2 expression in target cells

very low  
low  
medium  
high

RBD-targeting antibodies
 depleted  
not depleted

Fraction infectivity

sérum 1  
sérum 2  
sérum 3  
sérum 4  
sérum 5  
sérum 6  
sérum 7  
sérum 8  
sérum 9  
sérum 10

\[ \text{Log}_{10} \text{serum dilution} \]
Fig. S3. Spike-pseudotyped lentiviral particle neutralization with RBD-depleted and non-depleted sera summarized in Fig 2. Pseudovirus neutralization for RBD-depleted and non-depleted sera was measured on cells expressing different amounts of ACE2. IC$_{50}$ values were calculated using the neutcurve software package (https://jbloomlab.github.io/neutcurve/, version 0.5.7), by fitting a Hill curve and fixing the top of the curve to one and bottom to zero. NT$_{50}$ values from these neutralization curves were used to plot Fig 2B and calculate values for Figures 2C and D.
Table S1: Characteristics of sera used in this study. Participant SARS-CoV-2 immune history, age, sex, illness severity, vaccine type, approximate sample collection date, days post second vaccine dose (at time of sample collection), and approximate date of symptom onset.

| Sample | SARS-CoV-2 immune history | Age | Sex | Illness severity | Vaccine | Sample collection date | Days post second dose | Symptom onset |
|--------|---------------------------|-----|-----|-----------------|---------|------------------------|-----------------------|---------------|
| Serum 1 | Vaccinated 2x, previously infected | 36  | Female | Mild, non-hospitalized | Pfizer | Jan-Feb 2021 | 10 | Mar 2020 |
| Serum 2 | Vaccinated 2x, previously infected | 72  | Female | Mild, non-hospitalized | Pfizer | Mar-Apr 2021 | 15 | Mar 2020 |
| Serum 3 | Vaccinated 2x, previously infected | 50  | Male | Mild, non-hospitalized | Pfizer | May-Jun 2021 | 27 | Mar 2020 |
| Serum 4 | Vaccinated 2x, previously infected | 64  | Female | Mild, non-hospitalized | Pfizer | May-Jun 2021 | 18 | Mar 2020 |
| Serum 5 | Vaccinated 2x, previously infected | 47  | Female | Mild, non-hospitalized | Pfizer | Jan-Feb 2021 | 10 | Mar 2020 |
| Serum 6 | Vaccinated 2x, previously infected | 37  | Female | Mild, non-hospitalized | Moderna | May-Jun 2021 | 36 | Apr 2020 |
| Serum 7 | Vaccinated 2x, previously infected | 60  | Female | Mild, non-hospitalized | Pfizer | Mar-Apr 2021 | 9 | Mar 2020 |
| Serum 8 | Vaccinated 2x, previously infected | 53  | Male | Mild, non-hospitalized | Pfizer | Jan-Feb 2021 | 8 | Mar 2020 |
| Serum 9 | Vaccinated 2x, previously infected | 43  | Male | Mild, non-hospitalized | Pfizer | May-Jun 2021 | 19 | Mar 2020 |
| Serum 10 | Vaccinated 2x, previously infected | 41  | Female | Mild, non-hospitalized | Pfizer | May-Jun 2021 | 29 | Jun 2020 |
References

1. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583: 290–295.

2. Sholukh AM, Fiore-Gartland A, Ford ES, Miner MD, Hou YJ, Tse LV, et al. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. J Clin Microbiol. 2021;59: e0052721.

3. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593: 130–135.

4. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217. doi:10.1084/jem.20201181

5. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184: 2316–2331.e15.

6. Lempp FA, Sorriaga LB, Montiel-Ruiz M, Benigni F, Noack J, Park Y-J, et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature. 2021;598: 342–347.

7. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27: 717–726.

8. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584: 450–456.

9. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369: 650–655.

10. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184: 4220–4236.e13.

11. Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 0: eabq0203.

12. Shukla N, Roelle SM, Suzart VG, Bruchez AM, Matreyek KA. Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. PLoS Pathog. 2021;17: e1009715.

13. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020;12. doi:10.3390/v12050513

14. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. bioRxiv. 2020. p. 2020.06.08.140871. doi:10.1101/2020.06.08.140871

15. Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping
Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183: 1024–1042.e21.

16. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29: 463–476.e6.

17. Steffen TL, Taylor Stone E, Hassert M, Geerling E, Grimberg BT, Espino AM, et al. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. bioRxiv. 2020. p. 2020.08.21.261727. doi:10.1101/2020.08.21.261727

18. Schmidt F, Weisblum Y, Rutkowska M, Poston D, DaSilva J, Zhang F, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature. 2021;600: 512–516.

19. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci Transl Med. 2021;13. doi:10.1126/scitranslmed.abi9915

20. Luo S, Zhang J, Kreutzberger AJB, Eaton A, Edwards RJ, Jing C, et al. Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism. bioRxiv. 2022. p. 2022.06.26.497634. doi:10.1101/2022.06.26.497634

21. Qing E, Li P, Cooper L, Schulz S, Jäck H-M, Rong L, et al. Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Rep. 2022;39: 110786.

22. VanBlargan LA, Adams LJ, Liu Z, Chen RE, Gilchuk P, Raju S, et al. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity. 2021;54: 2399–2416.e6.

23. Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35: 109292.

24. Meng B, Datir R, Choi J, CITIID-NIHR Bioresource COVID-19 Collaboration, Bradley JR, Smith KGC, et al. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Cell Rep. 2022;40: 111220.

25. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A. 2002;99: 16249–16254.

26. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng K-W. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007;81: 13149–13157.

27. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375: 43–50.

28. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020;58. doi:10.1128/JCM.02107-20
29. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27: 1205–1211.

30. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39: e105114.

31. Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16: e9610.

32. Case JB, Mackin S, Errico J, Chong Z, Madden EA, Guarino B, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. bioRxiv. 2022. p. 2022.03.17.484787. doi:10.1101/2022.03.17.484787

33. Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun. 2020;11: 5214.

34. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020;58: e108.

35. Cohen AA, van Doremalen N, Greaney AJ, Andersen H, Sharma A, Starr TN, et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022;377: eabq0839.

36. Hsieh C-L, Werner AP, Leist SR, Stevens LJ, Falconer E, Goldsmith JA, et al. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep. 2021;37: 109929.

37. Matreyek KA, Stephany JJ, Chiasson MA, Hasle N, Fowler DM. An improved platform for functional assessment of large protein libraries in mammalian cells. Nucleic Acids Res. 2020;48: e1.

38. Neerukonda SN, Vassell R, Herrup R, Liu S, Wang T, Takeda K, et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS One. 2021;16: e0248348.

39. Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nat Commun. 2020;11: 4378.